Literature DB >> 15876288

Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London.

A H Mohsen1, S Murad, P J Easterbrook.   

Abstract

OBJECTIVES: There is limited information on the prevalence of and risk factors for hepatitis C virus (HCV) infection among HIV-1-infected patients in the UK. Our objective was to determine the prevalence of HCV infection among an ethnically diverse cohort of HIV-infected patients in south London, and to extrapolate from these data the number of co-infected patients in the UK.
METHODS: A total of 1017 HIV-1-infected patients who had attended King's College Hospital HIV clinic between September 2000 and August 2002 were screened for HCV antibody using a commercial enzyme-linked immunosorbent assay (ELISA). Positive results were confirmed by polymerase chain reaction (PCR) or recombinant immunoblot assay. Demographic, clinical and laboratory data were obtained from the local computerized database and medical records. We applied our HCV prevalence rates in the different HIV transmission groups to the estimated number of HIV-infected persons in these groups in the UK, to obtain a national estimate of the level of HIV-HCV co-infection.
RESULTS: Of the 1017 HIV-1-infected patients, 407 (40%) were white men, 158 (15.5%) were black African men, 268 (26.3%) were black African women, and 61 (6%) and 26 (2.6%) were black Caribbean men and women, respectively. Heterosexual exposure was the most common route of HIV acquisition (53.5%), followed by men having sex with men (36.9%), and current or previous injecting drug use (IDU) (7.2%). The overall prevalence of HCV co-infection was 90/1017 (8.9%), but this varied substantially according to route of transmission, from 82.2% among those with a history of IDU (which accounted for 67% of all HCV infections), to 31.8% in those who had received blood products, to 3.5% and 1.8% in those with homosexually and heterosexually acquired infection, respectively. Multivariate logistic regression analysis identified several independent risk factors for HCV infection: a history of IDU [odds ratio (OR) = 107.2; 95% confidence interval (CI) = 38.5-298.4], having received blood products (OR = 16.5; 95% CI = 5.1-53.7), and either being from a white ethnic group (OR = 4.3; 95% CI = 1.5-12.0) or being born in Southern Europe (OR = 6.7; 95% CI = 1.5-30.7). Based on the 35,473 known HIV-1-infected persons in the UK and the 10 997 estimated to be unaware of their status, we projected that there are at least 4136 HIV-HCV co-infected individuals in the UK and 979 who are unaware of their status.
CONCLUSIONS: Overall, 9% of our cohort was HIV-HCV co-infected. The prevalence was highest among intravenous drug users (82%), who accounted for most of our HCV cases, and lowest among heterosexual men and women from sub-Saharan Africa and the Caribbean [< 2%]. Our estimate that a significant number of co-infected persons may be unaware of their HIV and HCV status, highlights an urgent need to increase the uptake of HCV and HIV testing, particularly among injecting drug users, to reduce the risk of onward transmission.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15876288     DOI: 10.1111/j.1468-1293.2005.00291.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  11 in total

Review 1.  Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.

Authors:  Yaron Rotman; T Jake Liang
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

2.  Substance Abuse, Hepatitis C, and Aging in HIV: Common Cofactors that Contribute to Neurobehavioral Disturbances.

Authors:  Randi Melissa Schuster; Raul Gonzalez
Journal:  Neurobehav HIV Med       Date:  2012-02-16

3.  A systematic review of prospective memory in HIV disease: from the laboratory to daily life.

Authors:  Gunes Avci; David P Sheppard; Savanna M Tierney; Victoria M Kordovski; Kelli L Sullivan; Steven Paul Woods
Journal:  Clin Neuropsychol       Date:  2017-09-27       Impact factor: 3.535

4.  Factors Influencing Uptake of Rapid HIV and Hepatitis C Screening Among Drug Misusing Adult Emergency Department Patients: Implications for Future HIV/HCV Screening Interventions.

Authors:  Roland C Merchant; Allison K DeLong; Tao Liu; Janette R Baird
Journal:  AIDS Behav       Date:  2015-11

5.  Dual inhibition of HCV and HIV by ring-expanded nucleosides containing the 5:7-fused imidazo[4,5-e][1,3]diazepine ring system. In vitro results and implications.

Authors:  Ning Zhang; Peng Zhang; Andrea Baier; Lucyna Cova; Ramachandra S Hosmane
Journal:  Bioorg Med Chem Lett       Date:  2014-01-08       Impact factor: 2.823

Review 6.  Epidemiology of hepatitis C in Croatia in the European context.

Authors:  Tatjana Vilibic-Cavlek; Jasmina Kucinar; Bernard Kaic; Maja Vilibic; Nenad Pandak; Ljubo Barbic; Vladimir Stevanovic; Jasmina Vranes
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

Review 7.  Prevalence of hepatitis C virus infection among HIV+ men who have sex with men: a systematic review and meta-analysis.

Authors:  Ashly E Jordan; David C Perlman; Joshua Neurer; Daniel J Smith; Don C Des Jarlais; Holly Hagan
Journal:  Int J STD AIDS       Date:  2016-07-10       Impact factor: 1.359

8.  HIV and hepatitis C virus coinfection, Cameroon.

Authors:  Christian Laurent; Anke Bourgeois; Mireille Mpoudi; Christelle Butel; Eitel Mpoudi-Ngolé; Eric Delaporte
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883

9.  Problem drug use the public health imperative: what some of the literature says.

Authors:  Gez Bevan
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-12-16

10.  Hepatitis C Virus Infection in HIV Positive Attendees of Shiraz Behavioral Diseases Consultation Center in Southern Iran.

Authors:  Mohammad Ali Davarpanah; Farnaz Khademolhosseini; Abdolreza Rajaeefard; Alireza Tavassoli; Seyed Kamalaldin Yazdanfar; Abbas Rezaianzadeh
Journal:  Indian J Community Med       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.